oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2004 (English)In: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 22, no 12, p. 2321-2328Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Our aim was to determine whether the change in left ventricular (LV) mass in response to antihypertensive treatment could be predicted by multivariate analysis of single nucleotide polymorphisms (SNPs) in candidate genes reflecting pathways likely to be involved in blood pressure control.

METHODS: Patients with mild to moderate primary hypertension and LV hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta1 adrenoreceptor blocker atenolol (n = 49). A microarray-based minisequencing system was used for genotyping 74 SNPs in 25 genes. These genotypes were related to the change in LV mass index by echocardiography, after 12 weeks treatment as monotherapy, using stepwise multiple regression analysis.

RESULTS: The blood pressure reductions were similar and significant in both treatment groups. Two SNPs in two separate genes (the angiotensinogen T1198C polymorphism, corresponding to the M235T variant and the apolipoprotein B G10108A polymorphism) for those treated with irbesartan, and the adrenoreceptor alpha2A A1817G for those treated with atenolol, significantly predicted the change in LV mass. The predictive power of these SNPs was independent of the degree of blood pressure reduction.

CONCLUSION: SNPs in the angiotensinogen, apolipoprotein B, and the alpha2 adrenoreceptor gene predicted the change in LV mass during antihypertensive therapy. These results illustrate the potential of using microarray-based technology for SNP genotyping in predicting individual drug responses.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2004. Vol. 22, no 12, p. 2321-2328
Keywords [en]
minisequencing, single nucleotide polymorphism (SNP), genotyping, microarrays, hypertension, left ventricular hypertrophy, pharmacogenetics
National Category
Medical and Health Sciences Medical Genetics Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:oru:diva-69391DOI: 10.1097/00004872-200412000-00014ISI: 000225723500014PubMedID: 15614026Scopus ID: 2-s2.0-10244257519OAI: oai:DiVA.org:oru-69391DiVA, id: diva2:1254531
Available from: 2018-10-09 Created: 2018-10-09 Last updated: 2018-10-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Kurland, Lisa

Search in DiVA

By author/editor
Kurland, Lisa
In the same journal
Journal of Hypertension
Medical and Health SciencesMedical GeneticsCardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 102 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf